These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10404319)

  • 1. The postantibiotic effect of N-chlorotaurine on Staphylococcus aureus. Application in the mouse peritonitis model.
    Nagl M; Hengster P; Semenitz E; Gottardi W
    J Antimicrob Chemother; 1999 Jun; 43(6):805-9. PubMed ID: 10404319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-chlorotaurine and its analogues N,N-dichloro-2,2-dimethyltaurine and N-monochloro-2,2-dimethyltaurine are safe and effective bactericidal agents in ex vivo corneal infection models.
    Teuchner B; Eitzinger C; Lutz M; Hager T; Schmid E; Bechrakis NE; Zuck M; Jekle A; Debabov D; Anderson M; Nagl M
    Acta Ophthalmol; 2012 Dec; 90(8):e632-7. PubMed ID: 22971221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial activity of dexamethasone and its combination with N-chlorotaurine.
    Neher A; Arnitz R; Gstöttner M; Schäfer D; Kröss EM; Nagl M
    Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):615-20. PubMed ID: 18559728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis--a double-blind, randomized, phase-2 clinical trial.
    Teuchner B; Nagl M; Schidlbauer A; Ishiko H; Dragosits E; Ulmer H; Aoki K; Ohno S; Mizuki N; Gottardi W; Larcher C
    J Ocul Pharmacol Ther; 2005 Apr; 21(2):157-65. PubMed ID: 15857282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorine covers on living bacteria: the initial step in antimicrobial action of active chlorine compounds.
    Gottardi W; Nagl M
    J Antimicrob Chemother; 2005 Apr; 55(4):475-82. PubMed ID: 15761074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity of micromolar N-chlorotaurine: evidence for its antimicrobial function in the human defense system.
    Nagl M; Hess MW; Pfaller K; Hengster P; Gottardi W
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2507-13. PubMed ID: 10952603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbicidal activity of N-chlorotaurine can be enhanced in the presence of lung epithelial cells.
    Leiter H; Toepfer S; Messner P; Rabensteiner M; Gostner JM; Lackner M; Hermann M; Nagl M
    J Cyst Fibros; 2020 Nov; 19(6):1011-1017. PubMed ID: 32201161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.
    Yang Y; Qian M; Yi S; Liu S; Li B; Yu R; Guo Q; Zhang X; Yu C; Li J; Xu J; Chen W
    PLoS One; 2016; 11(2):e0149460. PubMed ID: 26926145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activity of N-chlorotaurine against biofilm-forming bacteria grown on metal disks.
    Coraça-Huber DC; Ammann CG; Fille M; Hausdorfer J; Nogler M; Nagl M
    Antimicrob Agents Chemother; 2014; 58(4):2235-9. PubMed ID: 24492358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    JAMA; 1997 Sep; 278(11):891-2. PubMed ID: 9302229
    [No Abstract]   [Full Text] [Related]  

  • 11. Postantibiotic effect and postantibiotic sub-minimum inhibitory concentration effect of valnemulin against Staphylococcus aureus isolates from swine and chickens.
    Zhao DH; Yu Y; Zhou YF; Shi W; Deng H; Liu YH
    Lett Appl Microbiol; 2014 Feb; 58(2):150-5. PubMed ID: 24117872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections.
    Domenech A; Ribes S; Cabellos C; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    Microb Drug Resist; 2004; 10(4):346-53. PubMed ID: 15650381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid resistance in a clinical isolate of Staphylococcus aureus.
    Tsiodras S; Gold HS; Sakoulas G; Eliopoulos GM; Wennersten C; Venkataraman L; Moellering RC; Ferraro MJ
    Lancet; 2001 Jul; 358(9277):207-8. PubMed ID: 11476839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isovalerylshikonin, a new resistance-modifying agent from Arnebia euchroma, supresses antimicrobial resistance of drug-resistant Staphylococcus aureus.
    He JM; Sun SC; Sun ZL; Chen JT; Mu Q
    Int J Antimicrob Agents; 2019 Jan; 53(1):70-73. PubMed ID: 30176356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
    Shi G; Chen X; Wang H; Wang S; Guo X; Zhang X
    J Antibiot (Tokyo); 2012 May; 65(5):229-36. PubMed ID: 22334239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antibacterial activity of novel synthetic cyclic peptides.
    Dartois V; Sanchez-Quesada J; Cabezas E; Chi E; Dubbelde C; Dunn C; Granja J; Gritzen C; Weinberger D; Ghadiri MR; Parr TR
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3302-10. PubMed ID: 16048940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-antibiotic agent ginsenoside 20(S)-Rh2 enhanced the antibacterial effects of ciprofloxacin in vitro and in vivo as a potential NorA inhibitor.
    Zhang J; Sun Y; Wang Y; Lu M; He J; Liu J; Chen Q; Zhang X; Zhou F; Wang G; Sun X
    Eur J Pharmacol; 2014 Oct; 740():277-84. PubMed ID: 25054686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.